Repatha clinical indications
Pro Research Analysisby 
Searched over 200M research papers
Repatha Clinical Indications: LDL Cholesterol Reduction and Cardiovascular Risk
Indications for Hypercholesterolemia and Familial Hypercholesterolemia
Repatha (evolocumab) is primarily indicated for patients with high cholesterol, especially those who cannot adequately control their low-density lipoprotein cholesterol (LDL-C) with standard treatments like statins and diet alone. It is approved for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and for those with clinical atherosclerotic cardiovascular disease (ASCVD) who require further LDL-C lowering 1Koren2022Kandasamy2017+6 MORE. Repatha is also approved for pediatric patients aged 10 years and older with HeFH to reduce LDL-C as an adjunct to diet and other LDL-C-lowering therapies .
Use in Atherosclerotic Cardiovascular Disease (ASCVD)
For patients with established ASCVD, such as those who have had heart attacks or strokes, Repatha is indicated to further reduce LDL-C when statins and other therapies are not enough. Clinical trials have shown that adding Repatha to maximally tolerated statin therapy can significantly lower LDL-C levels and reduce the risk of major cardiovascular events 1Kandasamy2017Scheen2023+2 MORE.
Adjunctive Therapy and Statin Intolerance
Repatha can be used as an adjunct to diet and statin therapy, with or without other lipid-lowering agents, in adults with primary hyperlipidemia, including both familial and non-familial forms. It is also indicated for patients who cannot tolerate statins, either alone or in combination with non-statin lipid-lowering therapies Wallemacq2017Markham2015Cda-Amc2024.
Dosage and Administration
Repatha is administered as a subcutaneous injection, either 140 mg every two weeks or 420 mg once a month for most adults. For adults with HoFH, the recommended dose is 420 mg once a month 1Wallemacq2017Cda-Amc2024.
Clinical Efficacy and Safety
Clinical studies have demonstrated that Repatha can reduce LDL-C by 50–77% in patients with HeFH or ASCVD and by about 30% in those with HoFH, when added to other lipid-lowering therapies 1Koren2022Wallemacq2017+1 MORE. The drug is generally well tolerated, with the most common side effects being mild, such as nasopharyngitis, upper respiratory tract infection, flu, back pain, and injection-site reactions 1Wallemacq2017Scheen2023.
Conclusion
Repatha is indicated for patients with high cholesterol who are at increased risk for cardiovascular events, particularly those with familial hypercholesterolemia or established ASCVD who need additional LDL-C lowering beyond what can be achieved with statins and diet. It is also an option for patients who are statin-intolerant. Repatha’s clinical benefits include significant LDL-C reduction and a favorable safety profile, making it a valuable therapy for managing high-risk cholesterol patients 1Koren2022Kandasamy2017+7 MORE.
Sources and full results
Most relevant research papers on this topic